Results 151 to 160 of about 19,663 (194)

Research progress of small molecule targeted drugs for non-small cell lung cancer. [PDF]

Front Oncol
Qiu T, Huang X.
europepmc   +1 more source

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation. [PDF]

Pharmaceut Med
Bartlett JA, Culver N, Santangelo M, Prpich A, Long E, Sagawa K, Shanker R, Xu H, Wilner K.   +8 more
europepmc   +1 more source

Long-term outcomes of ALK inhibitors in metastatic <i>ALK</i>-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level data. [PDF]

Transl Lung Cancer Res
Ossato A, Damuzzo V, Del Bono L, Gasperoni L, Lupi T, Colicchio A, Gori S, Inno A.   +7 more
europepmc   +1 more source

Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). [PDF]

Virus Res
Tjärnhage E, Våtsveen TK, Raki M, Nemazee D, Farhan H, Munthe L, Grodeland G.   +6 more
europepmc   +1 more source

Brain metastasis: Opportunities for novel therapies. [PDF]

Neurotherapeutics
Sarfraz Z, Kotecha R, Maharaj A, Ahluwalia MS.   +3 more
europepmc   +1 more source

Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis. [PDF]

BMC Cancer
Zhao M, Li J, Jiang Y, Shao H, Huang J, Tang W.   +5 more
europepmc   +1 more source

Safety recommendations for ALK tyrosine kinase inhibitors in non-small cell lung cancer: evidence from FAERS and CVARDD real-world databases. [PDF]

Front Oncol
Zhang Y, Zhang T, Yang Y, Zhang W, Ma Q, Li J, Li J, Yang X, Gong J, Wang X, Liang J.   +10 more
europepmc   +1 more source

Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States. [PDF]

Front Pharmacol
Huo G, Wang X, Song Y, Tian Y, Chen P.
europepmc   +1 more source

Exploratory multiomics analysis identifies WDR17 as a potential biomarker of tyrosine kinase inhibitor resistance in lung adenocarcinoma. [PDF]

Discov Oncol
Xu Y, Li L, Li Z, Yang Y, Xing H, Ma X, Zhang X.   +6 more
europepmc   +1 more source